Northfield Labs Reports Verified Data From Troubled Phase III PolyHeme Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryNorthfield Laboratories is moving ahead with plans to file a BLA for its investigational red blood cell substitute PolyHeme, despite protocol violations that triggered a data verification process and a planned safety analysis to gain insight on myocardial infarction data
You may also be interested in...
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.